

Imate 4-6-04

1646

Applicant: Gotwals, et al.
Application No.: 09/423,018
Filed: October 12, 2000
Page 1 of 2


Docket No. A018US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gotwals, et al.
Application No.: 09/423,018 Group Art Unit: 1646
Filed: July 14, 2003 Examiner: Janet L. Andres, Ph. D.
Title: TYPE II TGF-BETA RECEPTOR/IMMUNOGLOBULIN CONSTANT
REGION FUSION PROTEINS

EXPRESS MAIL NO. 332302972 US DEPOSITED: April 5, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service Express Mail under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, MS Patent Application.


CURTIS L. SCHRANDT

MS Patent Application.
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement (IDS) is submitted pursuant to 37 C.F.R. § 1.97 to make of record four references cited by the European Patent Office (EPO) in an office action issued in connection with the European Patent Application counterpart of the instant application. This IDS is submitted together with: (1) a copy of the relevant EPO office action; (2) a PTO Information Disclosure Statement form listing the references; and (3) copies of the cited references.

Applicants' counsel respectfully requests that the Examiner inform him promptly if additional information or documents are requested in connection with this IDS.

Applicant: Gotwals, et al.
Application No.: 09/423,018
Filed: October 12, 2000
Page 2 of 2

Docket No. A018US

The Examiner is requested to return a copy of the attached PTO Information Disclosure Statement form with the next Office Action or Notice of Allowance and is requested to indicate on that copy those of the listed references which she considered. It is requested that the information disclosed herein be made of record in this application.

Authorization is hereby given to charge Biogen Idec Deposit Account 02-2327 for all fees required in connection with the filing of this IDS. If the Patent and Trademark Office will not charge those fees to Biogen Idec Deposit Account 02-2327, authorization is hereby given to charge the fees in the alternative to Coleman, Sudol & Sapone Deposit Account 04-0838.

Respectfully submitted,




Kevin J. McGough

Reg. No. 31,279

Attorney for the Applicants

914-337-4082 (Office Number)

Of Counsel-Coleman, Sudol & Sapone
714 Colorado Avenue
Bridgeport, CT 06605-1601
(203) 366-3560
Date: April 1, 2004



Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	09/423,018
Filing Date	October 12, 2000
First Named Inventor	Gotwals, et al.
Art Unit	1646
Examiner Name	Janet L. Andres
Attorney Docket Number	A018US

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)				
		PCT WO94/09815	5/11/94	Celtrix Pharm.		
		PCT WO 94 178 28	8/18/94	BIOGEN, INC.		

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/423,018
Filing Date	October 12, 2000
First Named Inventor	Gotwals, et al.
Art Unit	1646
Examiner Name	Janet L. Andres
Attorney Docket Number	A018US

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		OKADOME, "Distinct roles of the intravellular domains of transforming growth factor, etc."; J. Biol. Chem., 12/9/94, 269(49) P30753-6.	
		ISAKA, "Gene therapy by TGF-beta-Receptor-IgC Fc chimera inhibited extracellular matrix, etc."; J. American Soc. Nephrology, 1996, 7(9), p. 1735	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.